journal article·2025-06Open access

A triple-targeting “nano-brake” remodeling the impaired immune microenvironment in skin lesions for psoriasis treatment

Ruijie Chen, Baiqun Duan, Shize Li, Yixuan Zhu, Zihao Huang, Dingchao Shen, Zhanzheng Ye, Yuqi Yan, Chenyu Qiu, Haoxiong Guan, Yinsha Yao, Jie Dong, Fugen Wu, Xinyu Jiang, Xianbao Shi, Longfa Kou

Abstract

Psoriasis, a prevalent immune-mediated chronic inflammatory skin ailment, has been linked to heightened oxidative stress and compromised immune tolerance. Immune checkpoint pathways, particularly the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) signaling axis, are instrumental in establishing and sustaining self-tolerance and regulating immune responses. Augmenting PD-1/PD-L1 interaction holds promise for curtailing the proliferation and activation of infiltrating T cells and curbing the release of inflammatory cytokines, thereby mitigating psoriasis induced by impaired immune tolerance. Consequently, neutralizing the surplus reactive oxygen species (ROS) in the affected skin and revitalizing local immune tolerance could represent a beneficial approach to psoriasis treatment. In light of these insights, this study introduced a bilirubin-based nanoparticle cloaked in IFN-γ-stimulated macrophage membrane (designated as IMφm@GBn or "nano-brake"). Treatment with IFN-γ conferred the macrophage membrane with heightened expression of pro-inflammatory cytokine receptor and PD-L1. As a result, the engineered IMφm@GBn not only scavenged excessive ROS in psoriatic lesions but crucially also absorbed a wide spectrum of pro-inflammatory cytokines. Furthermore, it inhibited the proliferation and activation of infiltrating T cells through augmented PD-1/PD-L1 interactions, thereby rebalancing the Th17/Treg ratio. In an in vivo psoriasis mouse model, the "nano-brake" was locally and accurately delivered to the dermis via microneedle, orchestrating the immune microenvironment of psoriasis and mitigating autoimmune damage linked to impaired immune tolerance. This approach significantly enhanced the therapeutic efficacy in ameliorating psoriasis-associated symptoms. This study sets an illuminating precedent for cell membrane-based biomimetic nano-formulations, holding broad implications for psoriasis treatment through multi-pronged immunomodulation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Psoriasis: Treatment and Pathogenesis · Immunotherapy and Immune Responses · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (69)

Show source-provided references
1. S100 proteins as novel therapeutic targets in psoriasis and other autoimmune diseases10.3390/molecules27196640 ↗
2. Psoriasis: epidemiology, clinical features, and quality of life10.1136/ard.2004.033217 ↗
3. Effiffifficacy of shodhana and sarvang takradhara therapy in the management of psoriasis A case study
4. Demographic and epidemiological drivers of global burden of psoriasis10.1111/ajd.13710 ↗
5. New topical therapies for psoriasis10.1007/s40257-021-00649-w ↗
6. The role of vitamin D in psoriasis: a review10.1111/ijd.12790 ↗
7. New insights in topical drug delivery for skin disorders: from a nanotechnological perspective10.1021/acsomega.2c08016 ↗
8. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities10.1007/s40259-022-00569-z ↗
9. Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events10.2147/DDDT.S200147 ↗
10. Therapeutic application and construction of bilirubin incorporated nanoparticles10.1016/j.jconrel.2020.08.054 ↗
11. Pharmacological actions and therapeutic potentials of bilirubin in islet transplantation for the treatment of diabetes10.1016/j.phrs.2019.104256 ↗
12. Hyaluronic acid coated bilirubin nanoparticles attenuate ischemia reperfusion-induced acute kidney injury10.1016/j.jconrel.2021.04.033 ↗
13. Bilirubin nanomedicine ameliorates the progression of experimental autoimmune encephalomyelitis by modulating dendritic cells10.1016/j.jconrel.2021.01.019 ↗
14. Self-assembled nanoparticles with bilirubin/JPH203 alleviate imiquimod-induced psoriasis by reducing oxidative stress and suppressing Th17 expansion10.1016/j.cej.2021.133956 ↗
15. Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses10.1038/s41423-020-0465-0 ↗
16. Immuno-engineered nanodecoys for the multi-target anti-inflammatory treatment of autoimmune diseases10.1002/adma.202108817 ↗
17. Reactive oxygen species-responsive gel-based microneedle patches for prolonged and intelligent psoriasis management10.1021/acsnano.2c08979 ↗
18. Dendritic cells in the regulation of immunity and inflammation10.1016/j.smim.2017.12.002 ↗
19. Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function
20. Emerging role of PD-1/PD-L1 inhibitors in chronic liver diseases10.3389/fphar.2021.790963 ↗
21. Non-thermal atmospheric plasma ameliorates imiquimod-induced psoriasis-like skin inflammation in mice through inhibition of immune responses and up-regulation of PD-L1 expression
22. Ivashkiv. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
23. nterferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
24. Cell membrane and extracellular vesicle membrane‐coated nanoparticles: an envisaged approach for the management of skin conditions10.1002/VIW.20240043 ↗
25. Consensus statement on research and application of Chinese herbal medicine derived extracellular vesicles-like particles (2023 edition)10.1016/j.chmed.2023.11.002 ↗
26. Cellular nanovesicles with bioorthogonal targeting enhance photodynamic/photothermal therapy in psoriasis10.1016/j.actbio.2021.07.068 ↗
27. Ultraviolet B radiation-induced JPH203-loaded keratinocyte extracellular vesicles exert etiological interventions for psoriasis therapy10.1016/j.jconrel.2023.08.059 ↗
28. Hair follicle-targeting drug delivery strategies for the management of hair follicle-associated disorders
29. Dissolvable polymeric microneedles loaded with aspirin for antiplatelet aggregation
30. pH-activatable oxidative stress amplifying dissolving microneedles for combined chemo-photodynamic therapy of melanoma
31. Preparation of tanshinone IIA self-soluble microneedles and its inhibition on proliferation of human skin fibroblasts10.1016/j.chmed.2022.10.002 ↗
32. Enhanced uptake and anti-maturation effect of celastrol-loaded mannosylated liposomes on dendritic cells for psoriasis treatment10.1016/j.apsb.2021.07.019 ↗
33. Dual-targeting celecoxib nanoparticles protect intestinal epithelium and regulate macrophage polarization for ulcerative colitis treatment10.1016/j.cej.2022.139445 ↗
34. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response10.1038/s41586-018-0392-8 ↗
35. Immunosuppressive nanoparticles for management of immune-related adverse events in liver10.1021/acsnano.1c02391 ↗
36. Macrophage cell membrane‐cloaked nanoplatforms for biomedical applications10.1002/smtd.202200289 ↗
37. Role of interferon-gamma (IFN-γ) and IFN-γ receptor 1/2 (IFNγR1/2) in regulation of immunity, infection, and cancer development: IFN-γ-dependent or independent pathway10.1016/j.biopha.2022.113683 ↗
38. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy10.1038/s41577-018-0029-z ↗
39. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer10.1021/acsnano.6b03148 ↗
40. Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles10.1021/acs.nanolett.8b03439 ↗
41. Modulation of glucose metabolism through macrophage-membrane-coated metal-organic framework nanoparticles for triple-negative breast cancer therapy10.1016/j.cej.2023.148069 ↗
42. Bilirubin nanomedicine alleviates psoriatic skin inflammation by reducing oxidative stress and suppressing pathogenic signaling10.1016/j.jconrel.2020.07.015 ↗
43. Ultrasmall copper-based nanoparticles for reactive oxygen species scavenging and alleviation of inflammation related diseases10.1038/s41467-020-16544-7 ↗
44. A double-edged sword: ROS related therapies in the treatment of psoriasis
45. Bilirubin ameliorates osteoarthritis via activating Nrf2/HO-1 pathway and suppressing NF-kappaB signalling10.1111/jcmm.18173 ↗
46. Bilirubin improves the quality and function of hypothermic preserved islets by its antioxidative and anti-inflammatory effect10.1097/TP.0000000000002882 ↗
47. Bilirubin protects transplanted islets by targeting ferroptosis10.3389/fphar.2020.00907 ↗
48. Bilirubin nanoparticles alleviate sepsis-induced acute lung injury by protecting pulmonary endothelia glycocalyx and reducing inflammation
49. Transdermal delivery of indirubin-loaded microemulsion gel: preparation, characterization and anti-psoriatic activity
50. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis10.1016/j.jdermsci.2011.04.007 ↗
51. Oxidative stress as an important contributor to the pathogenesis of psoriasis10.3390/ijms21176206 ↗
52. Cytokines in psoriasis10.1016/bs.acc.2020.04.004 ↗
53. NHWD-1062 ameliorates inflammation and proliferation by the RIPK1/NF-kappaB/TLR1 axis in Psoriatic Keratinocytes10.1016/j.biopha.2023.114638 ↗
54. Regulatory T cells in autoimmune disease10.1038/s41590-018-0120-4 ↗
56. Pathophysiology, clinical presentation, and treatment of psoriasis: a review10.1001/jama.2020.4006 ↗
57. Signaling pathways and targeted therapies for psoriasis10.1038/s41392-023-01655-6 ↗
58. Nanoparticle-assisted transcutaneous delivery of a signal transducer and activator of transcription 3-inhibiting peptide ameliorates psoriasis-like skin inflammation10.1021/acsnano.8b02330 ↗
59. Alantolactone-loaded chitosan/hyaluronic acid nanoparticles suppress psoriasis by deactivating STAT3 pathway and restricting immune cell recruitment
60. Nano transdermal system combining mitochondria-targeting cerium oxide nanoparticles with all-trans retinoic acid for psoriasis
61. Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness10.3390/life12122050 ↗
62. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis10.1161/CIRCULATIONAHA.122.062551 ↗
63. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation10.1016/j.immuni.2013.11.020 ↗
64. Inflammasomes within hyperactive murine dendritic cells stimulate long-lived T cell-mediated anti-tumor immunity10.1016/j.celrep.2020.108381 ↗
65. Reduced IFN-γ receptor expression and attenuated IFN-γ response by dendritic cells in patients with atopic dermatitis10.1016/j.jaci.2011.05.043 ↗
66. Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis10.1093/intimm/dxq463 ↗
67. Circulating Myeloperoxidase (MPO)-DNA complexes as marker for Neutrophil Extracellular Traps (NETs) levels and the association with cardiovascular risk factors in the general population10.1371/journal.pone.0253698 ↗
68. NK/DC crosstalk-modulating antitumor activity via Sema3E/PlexinD1 axis for enhanced cancer immunotherapy10.1007/s12026-024-09536-y ↗
69. Macrophage membrane-based biomimetic nanocarrier system for enhanced immune activation and combination therapy in liver cancer10.1007/s13346-024-01690-y ↗